He also served as a United States Marine Corps infantry officer during the intervening period. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985. Hugin is past Chairman of the Boards of The Pharmaceutical Research and Manufacturers of America and the Healthcare Institute of NJ. He is a longstanding Member of the Board of Trustees of Family Promise, a national non-profit network assisting homeless families, and Director of the Parker Institute for Cancer Immunotherapy.
Hugin is currently Chair of the Board of the Garden State Initiative, a nonpartisan research and educational organization focused on economic issues in New Jersey.
Hugin also serves as a Director of Chubb Limited, Member of the Board of Trustees of Princeton University and Chair of The Darden School Foundation, University of Virginia. He is a noted health expert, who advocated for the importance of business development collaborations, innovations in science and improved patient access. Hugin has been appointed to Allergans Board of Directors, effective immediately. Under his leadership, Celgene saw unprecedented results across all facets of the company and grew by over $30 billion in market capitalization. 19, 2019 /PRNewswire/ - Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Robert J.
Until his retirement in 2018, he was the Chairman of the Board of Directors, serving as Executive Chairman from 2016 to 2018. He is currently Celgene's executive chairman, but Hugin joined the company back in 1999 as CFO and served as CEO for nearly six years prior to passing the. Hugin joined Celgene in 1999 as Chief Financial Officer and served in positions of increasing responsibility during his 19-year tenure with the company, including Executive Chairman, Chief Executive Officer, President and Chief Operating Officer.
0 kommentar(er)
